<DOC>
	<DOCNO>NCT00586794</DOCNO>
	<brief_summary>Eisenmenger 's syndrome present severe clinical picture polymorbidity constitute great burden individual well familial social level . The combination critically increase pulmonary vascular resistance , progressive pressure load right ventricle disturbance pulmonary gas exchange result long-term polymorbidity . The objective study provide evidence improvement patient exercise tolerance well general condition treatment oral sildenafil specific pulmonary vasodilator .</brief_summary>
	<brief_title>Therapy Pulmonary Arterial Hypertension ( PAH ) - Treatment With Sildenafil Eisenmenger Patients</brief_title>
	<detailed_description>Eisenmenger 's syndrome present severe clinical picture polymorbidity constitute great burden individual well familial social level . The combination critically increase pulmonary vascular resistance , progressive pressure load right ventricle disturbance pulmonary gas exchange result long-term polymorbidity . While patient 's ability care him-/ get lose time , financial burden due need medical consultation hospital stay increase . This distress patient family . Usually , death result cardiac decompensation presence gradually increase pulmonary vascular resistance hypoxic lesion organ include myocardium ( Hopkins , AJC 2002 ) . With good understand pathophysiology underlie pulmonary hypertension , novel therapeutic approach develop past year . These include ) inhibition NO-cGMP-degrading type 5 phosphodiesterase ( PDE-5 ) b ) antagonise endothelin system ( Krum , Curr Opin Investig Drugs 2003 ) . The goal dilatation abnormally constrict pulmonary arterial vessel relaxation vascular smooth muscle cell reversal pulmonary vascular remodelling ( Ghofrani , Pneumologie 2002 ) . Specific drug affect pulmonary vascular resistance study . Intravenous prostacyclin major disadvantage : high cost , tachyphylaxis , risk infection rebound hypertension upon discontinuation . Inhalative pulmonary vasodilator , particular iloprost , may effective primary pulmonary hypertension ( Olschewski , Ann Int Med 1996 ; Hoeper , Pneumologie 2001 ) , administration time-consuming , due mode application effect intermittent , last 75 minute ( Hoeper , JACC 2000 ) . Considering , oral treatment appear preferable , easy administration , hence , good patient compliance . Sildenafil ( Revatio® ) inhibitor phosphodiesterase 5 ( PDE-5 ) use many individual case ( Abrams , Schulze-Neick et al , Heart 2000 ) , acute study two long-term study human reduce pulmonary vessel resistance . Significant effect reduction pulmonary vessel resistance demonstrate combination inhalational prostanoid ( Ghofrani et al , Ann Int Med 2002 ) .Good long-term tolerability effectiveness period two year demonstrate work group . The objective study provide evidence improvement patient exercise tolerance well general condition treatment oral sildenafil specific pulmonary vasodilator . The data obtain suppose contribute development guideline treatment Pulmonary Arterial Hypertension ( PAH ) cause congenital heart defect . The hypothesis : 1 . Sildenafil heal specific pulmonary vascular damage , occur hypercirculation quick-acting inhibiting vasoconstriction . 2 . Through reduction pulmonary vessel resistance normalization pulmonary reagibility patient Eisenmenger syndrome . 3 . Pulmonary blood circulation systemic arterial oxygen delivery increase . 4 . The patient benefit improve exercise tolerance well general clinical condition . These hypothesis test compare finding follow examination , 52 78-week treatment sildenafil : clinical examination , Electrocardiogram ( ECG ) , echocardiography , ergospirometry , Magnetic Resonance Imaging ( MRI ) , cardiac catheterization pulmonary artery manometry , laboratory test .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Nonspecific : 1 . Written inform consent obtain . 2 . No participation another AMG driven study attendancing treatment protocol Specific : 1 . Age least 14 year 2 . Presence cyanosis &lt; 93 % arterial oxygen saturation ( measure transcutaneous pulse oximetry ) 3 . Clinical indication invasive diagnostic procedure plan study give ; evaluate basis observation , medicinal therapy ) 4 . Presence PAH diagnose invasive method Rp : Rs &gt; 0.5 measured rest , test pulmonary vasodilatory reserve 5 . One follow diagnosis : 1. noncorrected large congenital shunt defect atrial , ventricular arterial level : PAPVD ASD SVD VSD AVSD TAC APW PDA combination thereof . 2 . Surgically correct shunt defect ( diagnosis ) significant residual defect 3 . Other diagnosis univentricular physiology/ hemodynamics . Nonspecific : 1. pregnancy lactation 2. woman childbearing age sexually active without practise highly effective method contraception 3. disease impairment , opinion investigator exclude subject participation 4. substance abuse ( alcohol , medicine , drug ) 5. medical , psychological social circumstance would adversely affect patient 's ability participate reliably study increase risk others participate 6. insufficient compliance 7. miss willingness storaging transfer pseudonymous disease data within study . 8. subject able perform CardioPulmonary Exercise Testing ( CPX ) . Specific : 1. pulmonary hypertension secondary etiology specify inclusion criterion 2. subject know intolerance NO iloprost constituent 3. acute decompensated heart failure within 7 day invasive diagnostic procedure 4. clinically significant haemoptysis within last 6 month 5. hemodynamic instability would represent unjustifiable risk test pulmonary arterial vasoreagibility 6. arterial hypotension ( define agespecific value ) 7. anemia ( Hb &lt; 10 g/dl ) 8. decompensated symptomatic policythemia ; ( detail : 4.2.2. exclusion criterion ) 9. thrombocytopenia ( &lt; 50.000/µl ) 10. secondary impairment organic function : impairment renal function ( GFR &lt; 30 ml/min/1,73 m2 BSA ) impairment hepatic function ( ALT and/or AST &gt; 3 x ULN bilirubin ≥ 2 mg/dl ) 11. source pulmonary blood flow prohibit measurement blood flow lung therefore pulmonary vascular resistance : Glenn BT shunt significant number MAPCAs ; ( detail : 4.2.2. exclusion criterion ) 12 . Obstruction pulmonary blood outflow : obstruction pulmonary venous return mitral valve dysfunction 13 . Left heart disease : aortic mitral valve disease ( severe `` mild '' ) restrictive congestive cardiomyopathy PCWP/LVEDP &gt; 15 mmHg symptomatic coronary artery disease 14 . Significant valvular disease tricuspid pulmonary regurgitation ( exclusion criterion ; detail : 4.2.2. exclusion criterion ) . 15 . Pericardial constriction 16 . History stroke , myocardial infarction lifethreatening arrhythmia within 6 month screen 17 . Bronchopulmonary dysplasia ( BPD ) chronic lung diseases 18 . History significant pulmonary embolism 19 . Other relevant disease ( e.g . HIV , diabetes mellitus require medical treatment ) 20 . Subjects trisomy 21 ( reproducibility 6MWT CPX doubtful ; communication side effect subjective quality life doubtful ) 21. contraindication study medication ( see also `` 4.2.3 concomitant medication '' ) hypersensitivity active ingredient well supplementaries patient lose vision one eye due non arteriitic anterior ischaemic neuropathy opticus ( NAION ) . Prohibited concomitant medication : Any medication list discontinue least 30 day prior screen . Specific pulmonary vasodilator cardiac catheterization allow . 1 . Unspecified concomitant medication 2 . Other significant medication ( a.o . chronic intake systemic immunosuppression e.g . systemic glucocorticoid , cytostatic drug , ciclosporin ) 3 . Instable medication ( detail : 4.2.5 prohibit concomitant medication ) : begin new medication regimen within last 30 day screen change dosage exist medication within last 7 day cardiac catheterization 4 . Existing antipulmonary hypertensive medication ( form ) : PDE5 antagonist ( e.g . sildenafil ) prostanoids ( e.g . iloprost , prostacyclin , beraprost ) In case patient stable Bosentan therapy least 6 month . Bosentan ( Tracleer® ) unprohibited concomitant medication . 5 . Other medication vascular action : alpha blocker Larginin ( act NO axis ) ritonavir , nicorandil ( act K+ channel ) 6 . Medication compatible sildenafil interfere metabolism : cytochrome P450CYP2C9 CYP3A4 inhibitor ( e.g . erythromycin/ketoconazole/itraconazole/protease inhibitor ) exist medication , opinion investigator , may interfere sildenafil treatment .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Eisenmenger</keyword>
</DOC>